Global Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), By Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), By End User (Pharmaceutical Companies, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/4169
Anti-Cathepsin B Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 is expected to have a positive impact on the anti-cathepsin B market owing to research and development of anti-cathepsin B antibodies to cure the COVID-19 infection. For instance, a report published by the Shanghai Pasteur Institute of Chinese Academy of Sciences in February 2020 showed that when a SARS-CoV-2 (virus) enters a cell through ACE2 and undergoes endocytosis, cathepsin then degrades the spike protein (S protein) to release the nucleic acids of the virus. Some evidence shows that cathepsin B/L inhibitor can block this process. The growth of the anti-cathepsin market as a result of the COVID-19 pandemic has created lucrative opportunities for growth of the anti-cathepsin B market.
Furthermore, the increasing research and development of a wide range of products, and mergers and acquisitions among key players are the major factors that are expected to drive growth of the anti-cathepsin B market during the forecast period.
The increasing research and development of anti-cathepsin B by different research institutes is expected to contribute significantly to the anti-cathepsin B market growth. For instance, according to data published by the National Center for Biotechnology Information (NCBI) in January 2016, variety of cathepsin B inhibitors have been developed and investigated for the inhibition of tumor invasion to treat different cancers, however none have succeeded in demonstrating clinical evidence to treat cancers. However, what has been learned from the use of inhibitors to block cathepsin B function is still valuable and will provide insights in the development of clinically useful agents.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4169
As cathepsin B has been confirmed to play a vital role in invasion and metastasis, specific cathepsin B inhibitors will be more valuable for late stage cancers. In an immunocompetent model of breast cancer with spontaneous bone metastasis, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074, but not the broad spectrum cysteine cathepsin inhibitor JPM-OEt, reduced metastasis in tumor-bearing animals.
Several market players are focused on inorganic strategies such as mergers and acquisitions to expand their product portfolio and gain maximum share in the market. For instance, in November 2015, Germany’s Merck KGaA announced the completion of its US$ 17 billion acquisition of Sigma-Aldrich, following approval from the European Commission. Following the acquisition, Merck will have an offering of 300,000 products with highly-respected brands and products including cathepsin Inhibitors, around 50,000 employees in 67 countries, and working at 72 manufacturing sites worldwide. Along with Sigma-Aldrich, Merck has created strategic marketing and innovation teams (SMIs) to promote and deliver innovation tailored to its life science customers’ needs. Furthermore, Sigma-Aldrich and Merck will be able to serve life science customers around the world with a highly attractive set of established brands such as SAFC and BioReliance, in addition to Millipore and Milli-Q.
Browse 43 Market Data Tables and 39 Figures spread through 177 Pages and in-depth TOC on Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Forecast to 2027″
To know the latest trends and insights related to Anti-Cathepsin B market press release, click the link below: https://www.coherentmarketinsights.com/press-release/anti-cathepsin-b-market-3419
Key Takeaways of the Anti-Cathepsin B Market:
- The anti-cathepsin B market is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027) owing to the increasing research and development activities and clinical trials.
- Major players offering a wide range of products which is expected to boost growth of the anti-cathepsin B market during the forecast period. For example, Santa Cruz Biotechnology offers a broad range of cathepsin B Inhibitors and Cathepsin inhibitor peptides, E-64-d, E-64, Chymostatin, CA-074 methyl ester, Calpain Inhibitor VI, Mu-Phe-hPhe-FMK, E-64-c, CA-074, Cathepsin B inhibitor, Leupeptin trifluoroacetate salt, Caspase Inhibitor Negative Control, and Biotin-FA-FMK. Cathepsin B inhibitor is a cell-permeable, irreversible cathepsin B inhibitor that may be potentially useful in treating arthritis. Cathepsin B has been found to be involved in demyelination, emphysema, rheumatoid arthritis, and neoplastic infiltration.
- Major players operating in the anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc., and Abcam Plc.
Detailed Segmentation:
- Global Anti-Cathespin B Market, By Type:
- Primary Antibodies
- Proteins and Peptides
- Lysates
- Global Anti-Cathespin B Market, By Research Application:
- Cancer
- Traumatic Brain Injury
- Ebola Infection
- Fertility Treatment
- Others
- Global Anti-Cathespin B Market, By Technique:
- Immunohistochemistry
- Immunofluorescence
- Western Blotting
- ELISA
- Flow Cytometry
- Others
- Global Anti-Cathespin B Market, By End User:
- Pharmaceutical Companies
- Academic and Research Institutes
- Global Anti-Cathespin B Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Type:
- Primary Antibodies
- Proteins and Peptides
- Lysates
- By Research Application:
- Cancer
- Traumatic Brain Injury
- Ebola Infection
- Fertility Treatment
- Others
- By Technique:
- Immunohistochemistry
- Immunofluorescence
- Western Blotting
- ELISA
- Flow Cytometry
- Others
- By End User:
- Pharmaceutical Companies
- Academic and Research Institutes
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Type:
- By Research Application:
- By Technique:
- By End User:
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Type:
- By Research Application:
- By Technique:
- By End User:
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Type:
- By Research Application:
- By Technique:
- By End User:
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Type:
- By Research Application:
- By Technique:
- By End User:
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Type:
- By Research Application:
- By Technique:
- By End User:
- By Country/Region:
- North America
- Company Profiles
- Merck KGaA*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bio-Techne
- BioVision Inc.
- Santa Cruz Biotechnology, Inc.
- MedChemExpress
- BioCat GmbH
- ApexBio Technology
- Cayman Chemical
- Selleck Chemicals
- BOC Sciences
- AG Scientific
- Virobay Inc.
- Abcam Plc
- Merck KGaA*
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837